Screening and Risk Reduction Strategies for Breast Cancer

CHF 130.75
Auf Lager
SKU
CHL68R7DFVS
Stock 1 Verfügbar
Geliefert zwischen Di., 28.04.2026 und Mi., 29.04.2026

Details

This book provides readers with the most up-to-date practical information on breast cancer screening. Since breast cancers are highly heterogeneous, time to clinical onset from the initial carcinogenesis differs diversely between cancers. Pathological germline variants and driver mutations cause a high lifetime risk of breast cancer. The lifetime risks are various according to what genes are pathologically dysfunctional. Integrated omics and imaging technologies have established varying tumour characteristics. Thus, this book suggests that a more individualised scheme is required to improve breast cancer screening.

A key aim is to demonstrate how multiple diagnostic imaging modalities such as mammography, ultrasonography, MRI, PET and dbPET improve breast cancer screening accuracy. Mammography screening alone may have a limited impact on breast cancer risk prediction. These issues are crucial to discuss. Clinical experts recommend that new modalities be incorporated for women with dense breasts, like ultrasonography, dynamic mammography, MRI and maybe breast-dedicated PET. Topics on these modalities are going to be summarized in this book. An in-depth review of these modalities is summarised in this book. In addition, new diagnostic modalities, including risk assessment tools, multi-cancer early detection tests using liquid biopsy, the role of protein biomarkers in breast cancer risk screening, challenges, and hopes for future advances, are also covered in this book.



Touch upon current topics in breast cancer screening More individualized screening system for breast cancers are focused upon Possible understand background and advances on the risk reduction of breast cancers

Autorentext

Masakazu Toi, Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.


Inhalt

  1. Introduction of the whole issue.- 2. Breast cancer epidemiology: incidence, risks and subtype.- 3. Personalized genetic breast cancer risk estimation with polygenic risk scores.- 4. Mathematical model forassessing breast cancer risk.- 5. Cost-effectiveness Analysis of multigene testing.- 6. Hereditary breast cancer: Its biology, subtype and clinical phenotype.- 7. Surgical risk reduction of breast cancer.- 8. Medical risk reduction of breast cancer.- 9. Screening for breast cancer with mammography.- 10. Breast cancer screening: Weighing the benefits and harms.- 11. Breast cancer screening according to individual risk.- 12. MRI: Detection of noninvasive diseases.- 13. Significance of MRI for women having dense breasts .- 14. Ultrasound: screening of breast cancer.- 15. Detection of breast cancer by PET.- 16. Radiowave mammography.- 17. Photoacoustic imaging of breast cancer.

Weitere Informationen

  • Allgemeine Informationen
    • GTIN 09789811976322
    • Editor Masakazu Toi
    • Sprache Englisch
    • Auflage 2023
    • Größe H254mm x B178mm x T11mm
    • Jahr 2024
    • EAN 9789811976322
    • Format Kartonierter Einband
    • ISBN 9811976325
    • Veröffentlichung 03.03.2024
    • Titel Screening and Risk Reduction Strategies for Breast Cancer
    • Untertitel Imaging Modality and Risk-Reduction Approaches
    • Gewicht 441g
    • Herausgeber Springer Nature Singapore
    • Anzahl Seiten 204
    • Lesemotiv Verstehen
    • Genre Medical Books

Bewertungen

Schreiben Sie eine Bewertung
Nur registrierte Benutzer können Bewertungen schreiben. Bitte loggen Sie sich ein oder erstellen Sie ein Konto.
Made with ♥ in Switzerland | ©2025 Avento by Gametime AG
Gametime AG | Hohlstrasse 216 | 8004 Zürich | Schweiz | UID: CHE-112.967.470
Kundenservice: customerservice@avento.shop | Tel: +41 44 248 38 38